Find disease awareness content and relevant supporting materials
FDA approves Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)- AbbVie + Janssen Biotech
AbbVie announced that the FDA has approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)....
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy
The past two decades have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL), particularly with the introduction of targeted therapies to clinical practice.
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease
Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown.
Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia.- AstraZeneca
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib .